-Rapid Case Ascertainment (RCA) Shared Resource Rapid Case Ascertainment (RCA) is a unique population science shared resource that provides central support for population-based research by providing rapid ascertainment of cancer cases that occur across North Carolina. Rapid case ascertainment (identification within one month after diagnosis) is critical to the successful conduct of quality, population-based, epidemiologic and outcomes studies, including studies that incorporate molecular biology, biomarkers, and patient-reported outcomes. Since it started in 1993, RCA supported multiple large population science research studies of breast, colon, prostate, head and neck cancers and melanoma. These included case-control etiologic studies and outcomes-related studies of bladder and prostate cancer. Built on decades of close collaboration with the State of North Carolina?s Central Cancer Registry (CCR) RCA facilitates efficient and centralized case identification. Because of its long-standing collaborative relationship with hospitals in North Carolina, RCA also works with LCCC members to collect baseline and follow-up medical records for enrolled patients. Finally, RCA provides consultation and administrative assistance to researchers through the coordination of grant applications, IRB approvals, reports to hospitals and tumor registrars, database development, and activities among project investigators, the State of North Carolina?s CCR, and related state committees. The RCA shared resource provides centralized coordination ascertainment, especially for hospitals in rural and underserved counties in the Center?s catchment area (all of North Carolina). Case-finding takes place for multiple studies across hospitals, providing a high degree of efficiency and cost effectiveness for the studies. In 2014, the facility was used to identify 16,366 new cases of breast, meningioma, prostate, cervical, colorectal, ovarian and medullary thyroid cancer cases across all 100 counties in North Carolina. A unique and valuable resource, RCA collaborated with other NCI Cancer Centers by supporting NC population research with other cancer centers in NC and outside the state. UNC Lineberger investigators continue to expand their efforts in population-based studies that rely on rapid case ascertainment. The RCA shared resource requests $73,090 in CCSG funds, representing 21% of its total budget. Future plans include the implementation of new NC population-based epidemiologic, clinical, and health services studies and working with the CCR to obtain additional follow-up on the occurrence of second primary tumors and the timely assessment of vital status of cases enrolled in epidemiologic and other population studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614917
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications